Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 2,339 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.41, for a total value of $47,738.99. Following the completion of the transaction, the insider now directly owns 172,274 shares in the company, valued at $3,516,112.34. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Soleil Boughton also recently made the following trade(s):
- On Tuesday, September 17th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.50, for a total value of $38,593.50.
- On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25.
- On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20.
- On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.29, for a total transaction of $47,377.15.
Hims & Hers Health Stock Performance
Shares of HIMS stock opened at $21.56 on Friday. The stock’s fifty day moving average is $16.82 and its two-hundred day moving average is $17.53. The firm has a market capitalization of $4.63 billion, a P/E ratio of -2,156.00 and a beta of 1.06. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $25.74.
Analyst Ratings Changes
Several brokerages have weighed in on HIMS. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Jefferies Financial Group lifted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Finally, TD Cowen increased their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.07.
Get Our Latest Research Report on Hims & Hers Health
Hedge Funds Weigh In On Hims & Hers Health
A number of institutional investors have recently added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC increased its stake in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC increased its position in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC raised its stake in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new position in Hims & Hers Health in the 2nd quarter valued at about $111,000. Finally, Amalgamated Bank grew its stake in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Recommended Stories
- Five stocks we like better than Hims & Hers Health
- What is a support level?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- What is the Hang Seng index?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Technology Stocks Explained: Here’s What to Know About Tech
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.